-+ 0.00%
-+ 0.00%
-+ 0.00%

Wantai Biotech (603392.SH): Recombinant respiratory syncytial virus vaccine (CHO cells) clinical trial application accepted

Zhitongcaijing·12/17/2025 08:33:05
Listen to the news

Zhitong Financial App News, Wantai Biotech (603392.SH) announced that Xiamen Wantai Canghai Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, has received the “Notice of Acceptance” from the National Drug Administration (“State Drug Administration”), and the clinical trial application for the “recombinant respiratory syncytial virus vaccine (CHO cells)” declared by the company has been accepted.